Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation

NCT07583303 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT07583303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07583303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 14, 2026
Completion date
April 16, 2027
Enrollment
19 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent acute myeloid leukemia, refractory acute myeloid leukemia